Table of Contents
<< Previous Issue | Apr 2016 (Vol: 2016, Issue: 4) | Next Issue >> |
- Section: Licensing
-
Allergan Bolsters its CNS Pipeline with Heptares’ GPCR Targeted Therapies
- Section: Mergers & Acquisitions
-
BMS seeks to invigorate its autoimmune pipeline with acquisition of Padlock
-
Vectura Acquires SkyePharma for US$628 M to Lead in Inhalation Devices
-
Gilead Acquires NASH Candidate from Nimbus to Strengthen its Liver Disease Portfolio
- Section: Research & Development
-
Sanofi Signs US$2.26 B Deal with Start-Up DiCE Molecules to Develop Next-Generation Oral Therapeutics